Payment overview · 2025
General Payments
$1,779.39
47 reported records · 10 companies
Healthcare provider profile · identity verified
Luis A. Rivera, M.D.
Allopathic & Osteopathic Physicians|General Practice · SAN JUAN, PR · NPI 1376608984
Verified facts
What the public records show
CMS Open Payments records show Luis A. Rivera, M.D. received $1,779.39 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 555 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synjardy by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 342 records involving 186 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $569.60 | 32.0% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $337.53 | 19.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $262.11 | 14.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $171.82 | 9.7% | 7 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $150.96 | 8.5% | 6 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $122.26 | 6.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.80 | 4.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.02 | 2.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.44 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.85 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,779.39 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $313.70 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $239.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $196.51 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $150.96 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.58 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $122.26 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $97.57 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.30 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $70.80 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $24.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 329 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 178 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 555 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
555 | 120 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
329 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 342 supporting records · 186 recipient NPIs · example record 1186464879 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
97 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 731 | 190 |
| Gabapentin | Gabapentin | 684 | 173 |
| Synthroid | Levothyroxine Sodium | 555 | 120 |
| Losartan Potassium | Losartan Potassium | 541 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 132 |
| Simvastatin | Simvastatin | 495 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 370 | 103 |
| Metformin Hcl | Metformin Hcl | 330 | 90 |
| Farxiga | Dapagliflozin Propanediol | 329 | 60 |
| Clonazepam | Clonazepam | 279 | 58 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 278 | 50 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 219 | 50 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 204 | 39 |
| Lisinopril | Lisinopril | 203 | 49 |
| Diclofenac Potassium | Diclofenac Potassium | 202 | 83 |
| Ezetimibe | Ezetimibe | 198 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 196 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 53 |
| Jardiance | Empagliflozin | 178 | 37 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 176 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 170 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 38 |
| Humalog | Insulin Lispro | 135 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 46 |
| Alendronate Sodium | Alendronate Sodium | 132 | 30 |
| Famotidine | Famotidine | 130 | 40 |
| Sertraline Hcl | Sertraline Hcl | 128 | 28 |
| Carvedilol | Carvedilol | 122 | 33 |
| Omeprazole | Omeprazole | 121 | 34 |
| Irbesartan | Irbesartan | 118 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 28 |
| Glyxambi | Empagliflozin/Linagliptin | 112 | 21 |
| Furosemide | Furosemide | 108 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 103 | 29 |
| Valsartan | Valsartan | 101 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 32 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 98 | 18 |
| Enalapril Maleate | Enalapril Maleate | 97 | 24 |
| Trulicity | Dulaglutide | 97 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 95 | 21 |
| Ozempic | Semaglutide | 94 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 24 |
| Raloxifene Hcl | Raloxifene Hcl | 90 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 43 |
| Sulindac | Sulindac | 86 | 51 |
| Memantine Hcl | Memantine Hcl | 85 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 45 |
| Nabumetone | Nabumetone | 81 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 37 |
| Montelukast Sodium | Montelukast Sodium | 80 | 27 |
| Eliquis | Apixaban | 78 | 14 |
| Lansoprazole | Lansoprazole | 78 | 18 |
| Naproxen | Naproxen | 77 | 27 |
| Donepezil Hcl | Donepezil Hcl | 76 | 17 |
| Cilostazol | Cilostazol | 66 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Temazepam | Temazepam | 65 | 14 |
| Tramadol Hcl | Tramadol Hcl | 59 | 26 |
| Humalog Kwikpen U-100 | Insulin Lispro | 58 | 14 |
| Fenofibrate | Fenofibrate | 55 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 14 |
| Verapamil Er | Verapamil Hcl | 54 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 53 | 11 |
| Azithromycin | Azithromycin | 50 | 44 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Atenolol | Atenolol | 44 | 12 |
| Glimepiride | Glimepiride | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 43 | 15 |
| Humulin N | Insulin Nph Human Isophane | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Insulin Lispro | Insulin Lispro | 34 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Sucralfate | Sucralfate | 28 | 11 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Tadalafil | Tadalafil | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Benzonatate | Benzonatate | 19 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,779.39 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, LOKELMA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SYNTHROID, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error